Brief: Immunogen Says ELAHERE Demonstrates 35% Reduction In Risk Of Disease Progression Or Death Versus Chemotherapy

ImmunoGen

04/06/2023 13:07

June 4 (Reuters) - ImmunoGen Inc  IMGN.O :
    * ELAHERE DEMONSTRATES 35% REDUCTION IN RISK OF DISEASE
PROGRESSION OR DEATH VERSUS CHEMOTHERAPY IN FRΑ-POSITIVE
PLATINUM-RESISTANT OVARIAN CANCER
    * RESULTS FROM MIRASOL ALSO SHOW ELAHERE IS FIRST TREATMENT
TO
DEMONSTRATE AN OVERALL SURVIVAL BENEFIT IN A PHASE 3 TRIAL
    * CLINICALLY MEANINGFUL IMPROVEMENTS IN PROGRESSION FREE
SURVIVAL
AND OVERALL SURVIVAL OBSERVED WITH ELAHERE REGARDLESS OF PRIOR
BEVACIZUMAB STATUS
    * LOOK FORWARD TO SUBMITTING MAA AND SBLA FOR ELAHERE IN EU
AND
US, RESPECTIVELY, DURING SECOND HALF OF YEAR

Source text for Eikon:  ID:nBwJwpnRa 
Further company coverage:  IMGN.O 

 ((Reuters.Briefs@thomsonreuters.com;))